Doubling the dose: a new hope for psoriasis patients losing treatment benefits
NCT ID NCT01680159
Summary
This study tested whether doubling the dose of the drug TA-650 could help patients with moderate-to-severe psoriasis who initially responded to a standard dose but later saw their symptoms return. The trial involved 51 adults with different forms of psoriasis, including plaque psoriasis and psoriatic arthritis. Researchers gave participants a higher dose of the drug every 8 weeks to see if it could safely and effectively regain control of their skin and joint symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational site
Chugoku, Japan
-
Investigational site
Chūbu, Japan
-
Investigational site
Hokkaido, Japan
-
Investigational site
Kanto, Japan
-
Investigational site
Kinki, Japan
-
Investigational site
Kyushu, Japan
-
Investigational site
Tōhoku, Japan
Conditions
Explore the condition pages connected to this study.